EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Apixaban Use Before Kidney Transplantation: Is Reversal Necessary?

Laura Cotiguala iD, Anne Przybylski iD, Lance Linberger, Marissa Brokhof iD, Nicole Kenyon iD, Cara Joyce iD, Michelle Dierker iD, Katie Ferguson, Megan A Rech iD, Christine Trotter, Oswaldo Aguirre iD, Reynold I Lopez-Soler iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026

DOI: 10.1002/phar.70200 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2026. Verfasst von Laura Cotiguala und 11 weiteren Autor:innen. Beteiligte Einrichtung: Edward Hines Jr. VA Hospital, Hines, Illinois, USA. Hauptthemen laut MEDLINE: Pyridones, Kidney Transplantation, Pyrazoles, Factor Xa Inhibitors. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of apixaban prior to kidney transplantation is on the rise. However, optimal perioperative management remains uncertain, particularly regarding the need for preoperative reversal with four‐factor prothrombin complex concentrate (4F‐PCC). Prior reports suggest clinically relevant bleeding without reversal, but potential thrombotic consequences of prophylactic 4F‐PCC warrant caution. We hypothesized that withholding preoperative 4F‐PCC in patients taking apixaban before kidney transplantation would not increase early postoperative surgical‐bed bleeding.

Methods

This retrospective, two‐center study included adult kidney transplant recipients (KTRs) from January 2019 to September 2025 who had taken apixaban within 48 h before surgery. Patients were stratified by receipt versus nonreceipt of preoperative 4F‐PCC. The primary endpoint was surgical‐bed bleeding within 3 days of transplant. A one‐sided noninferiority test (margin of 15%) was used for the primary endpoint.

Results

Fifty KTRs were included, and 14 (28%) received preoperative 4f‐PCC and 36 (72%) did not. The median time since the last known apixaban dose was 21 h (interquartile range [IQR], 16–24 h) before transplant. Surgical‐bed bleeding occurred in 7.1% in the preoperative 4F‐PCC cohort and in 5.6% of the no preoperative 4F‐PCC cohort (differences, 1.6%; upper one‐sided confidence interval [CI], 21.5%; p = 0.11), suggesting similar event rates but not confirming noninferiority. No significant differences were observed between groups in transfusion requirements, delayed graft function, kidney function, venous thromboembolism (1 in the reversal group; 0 in the non‐reversal group), or reoperation. Two deaths occurred in the reversal group.

Conclusions

Withholding preoperative 4F‐PCC in apixaban‐treated KTR appears safe, with surgical‐bed bleeding rates comparable to those in patients who received preoperative 4F‐PCC. Findings support individualized rather than routine preoperative reversal strategies to balance bleeding and thrombotic risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesKidney TransplantationPyrazolesFactor Xa InhibitorsPostoperative HemorrhageBlood Coagulation FactorsHumansRetrospective StudiesFemaleMaleMiddle AgedPreoperative Care

Stichwörter der Autor:innen

Apixabankidney transplantationprothrombin complex concentratessurgical blood loss

Substanzen

PyridonesapixabanPyrazolesFactor Xa InhibitorsBlood Coagulation Factorsprothrombin complex concentrates

Autor:innen und Institutionen

  • Edward Hines Jr. VA Hospital, Hines, Illinois, USA.
  • Rush University Medical Center, Chicago, Illinois, USA.
  • Loyola University Medical Center, Maywood, Illinois, USA.
  • Department of Veterans Affairs, Center of Innovation for Complex Chronic Healthcare, Edward Hines, Jr. VA Hospital, Hines, Illinois, USA.
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.

ORCID-Profile: Laura Cotiguala, Anne Przybylski, Marissa Brokhof, Nicole Kenyon, Cara Joyce, Michelle Dierker, Megan A Rech, Oswaldo Aguirre, Reynold I Lopez-Soler

Zitieren

APA

Cotiguala, L., Przybylski, A., Linberger, L., Brokhof, M., Kenyon, N., Joyce, C., Dierker, M., Ferguson, K., Rech, M. A., Trotter, C., Aguirre, O., & Lopez-Soler, R. I. (2026). Apixaban Use Before Kidney Transplantation: Is Reversal Necessary?. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70200

Vancouver

Cotiguala L, Przybylski A, Linberger L, Brokhof M, Kenyon N, Joyce C, et al. Apixaban Use Before Kidney Transplantation: Is Reversal Necessary?. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026. doi:10.1002/phar.70200

BibTeX
@article{Cotiguala2026,
  author = {Cotiguala, Laura and Przybylski, Anne and Linberger, Lance and Brokhof, Marissa and Kenyon, Nicole and Joyce, Cara and Dierker, Michelle and Ferguson, Katie and Rech, Megan A and Trotter, Christine and Aguirre, Oswaldo and Lopez-Soler, Reynold I},
  title = {Apixaban Use Before Kidney Transplantation: Is Reversal Necessary?},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  doi = {10.1002/phar.70200}
}
Kostenlos starten →